These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32497624)

  • 1. Regulation of PD-1 in T cells for cancer immunotherapy.
    Yu X; Gao R; Li Y; Zeng C
    Eur J Pharmacol; 2020 Aug; 881():173240. PubMed ID: 32497624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: T Cell Exhaustion.
    Bonorino C; Mognol G
    Front Immunol; 2020; 11():920. PubMed ID: 32612599
    [No Abstract]   [Full Text] [Related]  

  • 5. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
    Liang B; Hu X; Ding Y; Liu M
    J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 9. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment.
    Kaltenmeier C; Yazdani HO; Morder K; Geller DA; Simmons RL; Tohme S
    Front Immunol; 2021; 12():785222. PubMed ID: 34899751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing T-cell Dysfunction and Exhaustion in Cancer.
    Zarour HM
    Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
    Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X
    Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
    Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation.
    Shimizu K; Sugiura D; Okazaki IM; Maruhashi T; Takegami Y; Cheng C; Ozaki S; Okazaki T
    Mol Cell; 2020 Mar; 77(5):937-950.e6. PubMed ID: 31926851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.
    Yao H; Wang H; Li C; Fang JY; Xu J
    Front Immunol; 2018; 9():1774. PubMed ID: 30105035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.